ANDOVER, Mass., July 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Tuesday, August 13, 2024, at 9:30 a.m. Eastern Standard Time.
Event: Canaccord Genuity 44th Annual Growth Conference
Date: Tuesday, August 13, 2024
Time: 9:30 a.m. ET
A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/.
About TransMedics Group, Inc.
TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact:
Brian Johnston
631-807-1986
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$93.50 |
| Daily Change: | -0.68 -0.72 |
| Daily Volume: | 1,286,732 |
| Market Cap: | US$3.140B |
February 27, 2025 February 18, 2025 October 28, 2024 April 30, 2024 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
